Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism

ESSENTIALS: Risk stratification for venous thromboembolism (VTE) in patients with brain tumors is challenging. Patients with IDH1 wildtype and high podoplanin expression have a 6‐month VTE risk of 18.2%. Patients with IDH1 mutation and no podoplanin expression have a 6‐month VTE risk of 0%. IDH1 mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Mir Seyed Nazari, P., Riedl, J., Preusser, M., Posch, F., Thaler, J., Marosi, C., Birner, P., Ricken, G., Hainfellner, J. A., Pabinger, I., Ay, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
CLINICAL HAEMOSTASIS AND THROMBOSIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099350/
https://www.ncbi.nlm.nih.gov/pubmed/29676036
http://dx.doi.org/10.1111/jth.14129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099350/
https://www.ncbi.nlm.nih.gov/pubmed/29676036
http://dx.doi.org/10.1111/jth.14129

Ejemplares similares